News
Devyser among Sweden’s Best Workplaces
We are extremely proud to have been recognized, once again, as one of Sweden’s Best Workplaces! This is a wonderful recognition of the teamwork and
Devyser completes private placement of SEK 130 million to Swedbank Robur and AP4
Stockholm, February 2, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced the completion of a private placement of 7,465 shares,
Devyser receives Eurostars grant to develop novel DNA test for early detection of transplant rejection
Devyser has been awarded a funding of EUR 750,000 through the Eurostars-2 program and will join its efforts with the University Hospital of Zurich to
Devyser receives MDSAP certification
We’re happy to announce that we’ve received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program
Case Study – A new NGS-based method for chimerism monitoring
New methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection of relapse and initiation of treatment to improve and save the lives
Major health care providers in Latin America implement Devyser’s solutions to improve post-transplant healthcare management
IMSS, Mexico’s largest public health care provider and INP, Mexico’s National Institute of Pediatrics, now use Devyser’s solutions for chimerism monitoring of transplanted patients Stockholm
Cancer doesn’t take a break, neither do we
We’re shipping! While the world focused on Covid-19 testing, cancer did not take a break. We’re so relieved that priorities are now diversifying to include
Devyser at DGTI 2020
Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to
Devyser welcomes Fredrik Alpsten as new CEO
Devyser welcomes Fredrik Alpsten as new CEO starting September 1st. Ulf Klangby, the former CEO and founder of Devyser, continues as COO and board member